RU2019120008A - Композиция на основе rmp и способы ее применения - Google Patents
Композиция на основе rmp и способы ее применения Download PDFInfo
- Publication number
- RU2019120008A RU2019120008A RU2019120008A RU2019120008A RU2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A RU 2019120008 A RU2019120008 A RU 2019120008A
- Authority
- RU
- Russia
- Prior art keywords
- rmp
- composition
- composition according
- paragraphs
- microns
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 238000000034 method Methods 0.000 title claims 7
- 210000003743 erythrocyte Anatomy 0.000 claims 6
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 4
- 229940022698 acetylcholinesterase Drugs 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010073391 Platelet dysfunction Diseases 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 229940125507 complex inhibitor Drugs 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000013467 fragmentation Methods 0.000 claims 1
- 238000006062 fragmentation reaction Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 108010014806 prothrombinase complex Proteins 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical group OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (16)
1. Композиция, содержащая полученные из эритроцитов микрочастицы (RMP), демонстрирующая ацетилхолинэстеразную (AchE) активность, которая составляет менее 350 пмоль/мин/106 частиц/мкл.
2. Композиция по п. 1, в которой RMP демонстрирует ацетилхолинэстеразную (AchE) активность, которая составляет менее 200 пмоль/мин/106 частиц/мкл.
3. Композиция по п. 1 или 2, отличающаяся тем, что 20%-50% RMP в композиции содержит фосфатидилсерин.
4. Композиция по п. 3, отличающаяся тем, что 30%-45% RMP в композиции содержит фосфатидилсерин.
5. Композиция по любому из пп. 1-4, отличающаяся тем, что указанная композиция сокращает время до образования начального сгустка, которое определяют тромбоэластографией (ТЭГ) в цельной крови и плазме, по меньшей мере на две минуты.
6. Композиция по любому из пп. 1-5, отличающаяся тем, что средний диаметр RMP составляет примерно 0,40-0,6 мкм.
7. Композиция по п. 6, отличающаяся тем, что средний диаметр RMP составляет примерно 0,40-0,5 мкм.
8. Композиция по п. 7, отличающаяся тем, что средний диаметр RMP составляет примерно 0,47 мкм.
9. Композиция по любому из пп. 1-8, отличающаяся тем, что внутренняя плотность RMP составляет менее 3,5% внутренней плотности целых эритроцитов.
10. Композиция по п. 9, отличающаяся тем, что внутренняя плотность RMP составляет примерно 0,5-3,0% внутренней плотности целых эритроцитов, как определено сигналом бокового рассеяния поточной цитометрии.
11. Композиция по любому из пп. 1-10, отличающаяся тем, что RMP получены посредством продавливания эритроцитов через отверстие с получением разрушенных эритроцитов и дальнейшей фрагментации разрушенных эритроцитов путем бомбардировки на твердой поверхности.
12. Способ лечения чрезмерного кровотечения у субъекта, где указанный способ включает введение субъекту композиции по любому из пп. 1-11.
13. Способ по п. 12, отличающийся тем, что чрезмерное кровотечение вызвано тромбоцитопенией или дисфункцией тромбоцитов.
14. Способ по п. 13, отличающийся тем, что дисфункция тромбоцитов вызвана лекарственной терапией.
15. Способ по п. 12, отличающийся тем, что чрезмерное кровотечение вызвано антикоагулянтом.
16. Способ по п. 15, отличающийся тем, что антикоагулянт представляет собой кумадин, низкомолекулярный гепарин, ингибитор комплекса протромбиназы, ингибитор FXa или ингибитор тромбина.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428155P | 2016-11-30 | 2016-11-30 | |
| US62/428,155 | 2016-11-30 | ||
| PCT/US2017/063700 WO2018102409A2 (en) | 2016-11-30 | 2017-11-29 | Rmp composition and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019120008A true RU2019120008A (ru) | 2021-01-13 |
| RU2019120008A3 RU2019120008A3 (ru) | 2021-03-09 |
| RU2768743C2 RU2768743C2 (ru) | 2022-03-24 |
Family
ID=62241842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120008A RU2768743C2 (ru) | 2016-11-30 | 2017-11-29 | Композиция на основе rmp и способы ее применения |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11241457B2 (ru) |
| EP (1) | EP3548092B1 (ru) |
| JP (2) | JP2020508963A (ru) |
| KR (2) | KR20190099436A (ru) |
| CN (1) | CN110799199B (ru) |
| AU (1) | AU2017367084B2 (ru) |
| BR (1) | BR112019010981A2 (ru) |
| CA (1) | CA3045144A1 (ru) |
| DK (1) | DK3548092T3 (ru) |
| ES (1) | ES2924134T3 (ru) |
| HR (1) | HRP20220892T1 (ru) |
| HU (1) | HUE059678T2 (ru) |
| IL (1) | IL266957B (ru) |
| LT (1) | LT3548092T (ru) |
| MX (1) | MX2019006354A (ru) |
| PL (1) | PL3548092T3 (ru) |
| PT (1) | PT3548092T (ru) |
| RS (1) | RS63537B1 (ru) |
| RU (1) | RU2768743C2 (ru) |
| SI (1) | SI3548092T1 (ru) |
| WO (1) | WO2018102409A2 (ru) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US5332578A (en) | 1989-04-14 | 1994-07-26 | Prp, Inc. | Platelet membrane microparticles |
| NZ279555A (en) * | 1994-02-14 | 1998-01-26 | Kirin Brewery | Thrombopoietin polypeptides their production and use |
| US5690963A (en) | 1995-06-30 | 1997-11-25 | The United States Of America As Represented By The Secretary Of The Navy | Freeze dried red blood cells |
| CA2348781A1 (en) | 1998-11-12 | 2000-05-25 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
| US20030040480A1 (en) | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US7294455B2 (en) * | 2003-05-16 | 2007-11-13 | The University Of North Carolina At Chapel Hill | Fixed-dried platelets cross-linked to protein |
| US7811558B2 (en) | 2004-08-12 | 2010-10-12 | Cellphire, Inc. | Use of stabilized platelets as hemostatic agent |
| US9155764B1 (en) * | 2004-12-07 | 2015-10-13 | University Of Miami | Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding |
| JP5204490B2 (ja) | 2004-12-07 | 2013-06-05 | ユニバーシティー オブ マイアミ | 出血の制御及び出血性疾患の治療のための止血剤としての細胞由来微粒子 |
| US20080057505A1 (en) | 2006-07-14 | 2008-03-06 | Ping Lin | Methods and compositions for detecting rare cells from a biological sample |
| EP2668262B1 (en) * | 2011-01-28 | 2017-11-29 | University of Miami | Expanded utility of red cell-derived microparticles (rmp) for treatment of bleeding |
| US10004764B2 (en) | 2013-11-07 | 2018-06-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Red blood cell membrane-derived microparticles and their use for the treatment of lung disease |
| WO2016141325A1 (en) | 2015-03-04 | 2016-09-09 | University Of Rochester | Systemic and topical application of platelet microparticles to treat bleeding in trauma patients |
-
2017
- 2017-11-29 PT PT178764841T patent/PT3548092T/pt unknown
- 2017-11-29 PL PL17876484.1T patent/PL3548092T3/pl unknown
- 2017-11-29 LT LTEPPCT/US2017/063700T patent/LT3548092T/lt unknown
- 2017-11-29 HR HRP20220892TT patent/HRP20220892T1/hr unknown
- 2017-11-29 US US16/465,054 patent/US11241457B2/en active Active
- 2017-11-29 KR KR1020197018762A patent/KR20190099436A/ko not_active IP Right Cessation
- 2017-11-29 JP JP2019529843A patent/JP2020508963A/ja active Pending
- 2017-11-29 KR KR1020247007757A patent/KR20240049569A/ko not_active Application Discontinuation
- 2017-11-29 CN CN201780074200.3A patent/CN110799199B/zh active Active
- 2017-11-29 DK DK17876484.1T patent/DK3548092T3/da active
- 2017-11-29 MX MX2019006354A patent/MX2019006354A/es unknown
- 2017-11-29 RS RS20220717A patent/RS63537B1/sr unknown
- 2017-11-29 RU RU2019120008A patent/RU2768743C2/ru active
- 2017-11-29 WO PCT/US2017/063700 patent/WO2018102409A2/en unknown
- 2017-11-29 ES ES17876484T patent/ES2924134T3/es active Active
- 2017-11-29 AU AU2017367084A patent/AU2017367084B2/en active Active
- 2017-11-29 CA CA3045144A patent/CA3045144A1/en active Pending
- 2017-11-29 HU HUE17876484A patent/HUE059678T2/hu unknown
- 2017-11-29 BR BR112019010981A patent/BR112019010981A2/pt unknown
- 2017-11-29 SI SI201731199T patent/SI3548092T1/sl unknown
- 2017-11-29 EP EP17876484.1A patent/EP3548092B1/en active Active
-
2019
- 2019-05-28 IL IL266957A patent/IL266957B/en unknown
-
2022
- 2022-10-28 JP JP2022173557A patent/JP2023017857A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3548092T3 (pl) | 2022-10-10 |
| EP3548092A4 (en) | 2021-01-27 |
| IL266957A (en) | 2019-07-31 |
| US20190321406A1 (en) | 2019-10-24 |
| DK3548092T3 (da) | 2022-08-01 |
| CA3045144A1 (en) | 2018-06-07 |
| RS63537B1 (sr) | 2022-09-30 |
| KR20190099436A (ko) | 2019-08-27 |
| RU2768743C2 (ru) | 2022-03-24 |
| BR112019010981A2 (pt) | 2019-10-15 |
| WO2018102409A3 (en) | 2019-12-05 |
| CN110799199A (zh) | 2020-02-14 |
| KR20240049569A (ko) | 2024-04-16 |
| ES2924134T3 (es) | 2022-10-04 |
| PT3548092T (pt) | 2022-08-09 |
| RU2019120008A3 (ru) | 2021-03-09 |
| HUE059678T2 (hu) | 2022-12-28 |
| JP2020508963A (ja) | 2020-03-26 |
| AU2017367084A1 (en) | 2019-06-20 |
| LT3548092T (lt) | 2022-10-10 |
| WO2018102409A2 (en) | 2018-06-07 |
| EP3548092B1 (en) | 2022-07-06 |
| CN110799199B (zh) | 2024-01-30 |
| EP3548092A2 (en) | 2019-10-09 |
| AU2017367084B2 (en) | 2023-11-23 |
| JP2023017857A (ja) | 2023-02-07 |
| MX2019006354A (es) | 2019-10-21 |
| IL266957B (en) | 2022-05-01 |
| HRP20220892T1 (hr) | 2022-10-14 |
| SI3548092T1 (sl) | 2022-10-28 |
| US11241457B2 (en) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garraud et al. | Are platelets cells? And if yes, are they immune cells? | |
| Levi et al. | The role of ADAMTS‐13 in the coagulopathy of sepsis | |
| Moore et al. | Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid | |
| Nording et al. | Platelets in inflammation and atherogenesis | |
| Feltracco et al. | Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation | |
| BR112016010067A2 (pt) | partícula de polímero e método de preparação | |
| US20140154234A1 (en) | Method for generating thrombin | |
| MX2020001913A (es) | Enzimas dnasa modificadas y uso en terapia. | |
| Guzmán-Uribe et al. | Thrombosis in leukemia: incidence, causes, and practical management | |
| WO2011115712A3 (en) | Tfpi inhibitors and methods of use | |
| Pabinger et al. | Flamethrowers: blood cells and cancer thrombosis risk | |
| BR112013031801B8 (pt) | artigo de fumar compreendendo material de tabaco contendo micropartículas não isométricas de carbonato de cálcio e seu método | |
| RU2019120008A (ru) | Композиция на основе rmp и способы ее применения | |
| AR023408A1 (es) | Una particula de nucleo-corteza, un sistema polimerico de fases multiples adaptado para formar particulas que tiene al menos dos fases distintas yseparadas, un metodo para promover la separacion entre una primera fase de nucleo y una segunda fase de corteza, un latex que tiene particulas de nucleo-c | |
| EP2668262B1 (en) | Expanded utility of red cell-derived microparticles (rmp) for treatment of bleeding | |
| Levi et al. | Hemostatic abnormalities in critically ill patients | |
| NZ747528A (en) | Use of antiplatelet thrombolysin in the preparation of a medicament for treatment of thrombotic thrombocytopenic purpura | |
| CA2524412A1 (en) | Medium and method for preserving platelets, red blood cells, and other non-nucleus cells and platelets-containing composition | |
| Jing et al. | The central role of extracellular vesicles in the mechanisms of thrombosis in COVID-19 patients with cancer and therapeutic strategies | |
| Yu et al. | Effects of 6-(4-chlorophenoxy)-tetrazolo [5, 1-a] phthalazine on Anticoagulation in Mice and the Inhibition of Experimental Thrombosis in Rats | |
| FR3014319B1 (fr) | Preparations injectables a base de collagenes capables de controler les saignements et/ou de se substituer a des plaquettes dans le cas de syndromes hemorragiques | |
| Wei et al. | Unraveling the Intricate Web: Complement Activation Shapes the Pathogenesis of Sepsis-Induced Coagulopathy | |
| Herbig et al. | Pathological VWF fibers resist tPA and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation | |
| Khoshimov et al. | Change of functional activity a part system of a hemostasis under the influence of | |
| Diamond | When flow goes slow, von Willebrand Factor can bind red blood cells |